| 发明名称 |
METHODS FOR TREATING CANCER |
| 摘要 |
The present invention relates to methods and materials for treating an individual with KRAS-mutated cancer or a cancer in which ROCK is inhibited independently of mutated KRAS. The invention is based on the prevention or disruption of the binding of TRAIL-Receptor to its ligand, TRAIL, in vivo, for example by use of an agent that neutralises TRAIL and/or a the TRAIL-Receptor (such TRAIL-R2) and/or diminishes TRAIL/TRAIL-Receptor activity, thereby reducing cancer cell transformation, migration and metastasis, prolonging survival of patients. |
| 申请公布号 |
US2016297865(A1) |
申请公布日期 |
2016.10.13 |
| 申请号 |
US201414902966 |
申请日期 |
2014.07.03 |
| 申请人 |
UCL BUSINESS PLC |
发明人 |
Walczak Henning;Von Karstedt Silvia |
| 分类号 |
C07K14/705;C07K16/28;G01N33/574;C07K16/24 |
主分类号 |
C07K14/705 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating an individual with a KRAS-mutated cancer, or a cancer in which ROCK is inhibited independently of KRAS mutation, the method comprising administering to the individual a therapeutically-effective amount of an agent that neutralises TNF-related apoptosis-inducing ligand (TRAIL) and/or a TRAIL-receptor (TRAIL-R) and/or diminishes TRAIL/TRAIL-R activity. |
| 地址 |
Greater London GB |
